Latest issue 08 Jul 2026

CRC Research Update — July 08, 2026

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

Phase 3 trial of Krazati plus Erbitux misses survival endpoints in KRAS G12C colorectal cancer
The confirmatory Krystal-10 study in 461 patients with previously treated KRAS G12C-mutated metastatic colorectal cancer failed to achieve statistical significance on both progression-free survival and overall survival when compared to chemotherapy. (Fierce Pharma)
Multi-state study examines colonoscopy use and persistent disparities in early-onset colorectal cancer
A nested case-control study of 2,776 patients analyzed predictors of early-onset colorectal cancer, temporal trends in colonoscopy utilization from 2017-2023, and differential predicted risk by health care engagement and ethnicity. (Surgery)
Sodium ferulate plus methylcobalamin shows benefit for oxaliplatin-induced neuropathy
A retrospective study of 280 colorectal cancer patients found that combining sodium ferulate with methylcobalamin improved outcomes for oxaliplatin-induced peripheral neuropathy, a common dose-limiting side effect that affects quality of life and treatment adherence. (British Journal of Hospital Medicine)
Review highlights gut microbiota's role in immunotherapy response, especially for MSI-H tumors
A comprehensive review evaluates how gut microbiota and microbial metabolites influence colorectal cancer development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for proficient mismatch repair/microsatellite-stable tumors where efficacy remains limited. (Life Sciences)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Colonoscopy trends and disparities in early-onset CRC examined across multiple states
Researchers analyzed 1,388 early-onset colorectal cancer patients to understand whether rising disease burden reflects increased screening or a true epidemiologic shift, with focus on racial and ethnic differences. (Surgery)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial
The Krystal-10 study did not meet primary endpoints in 461 patients with KRAS G12C-mutated metastatic colorectal cancer, raising questions about the drug's path to full FDA approval. (Fierce Pharma)
Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer
Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences)

These findings continue to advance our understanding of treatment options, screening approaches, and supportive care for the colorectal cancer community.

Subscribe to The CRC Digest